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We will describe the clinical case of a pregnant patient with chronic Immune Thrombocytopenic Purpura who develops
preeclampsia syndrome with HELLP syndrome. These concomitant and independent conditions become complex, resulting in
thrombocytopenia which creates diagnostic, prognostic and therapeutic inconveniences.
1.Introduction
Immune Thrombocytopenic Purpura (ITP) is a disease that
is present in approximately 1-2 of every 10,000 pregnancies
characterized by the formation of autoantibodies which
after binding to platelet antigens, destroy the platelets
in the reticuloendothelial system, mainly in the spleen,
causing thrombocytopenia [1]. There would be a decrease
in the production of platelets in the bone marrow due
to autoantibodies [2]. These autoantibodies are normally
lgGs that recognize platelet membrane glycoproteins, with
Glycoprotein (GP) llb/lIla and GP lb-IX being the most
frequent ones [3]. When the evolution of the disease lasts
beyond a period of six months, it is called “chronic” and can
be primary or secondary to other pathologies such as HIV or
malignant diseases.
Antiplateletautoantibodiesarefoundin60%–70%ofthe
cases [4]. It is a nonspeciﬁc characteristic since it appears in
otherpathologiessuchaspreeclampsia-eclampsiasyndrome,
HELLP syndrome, gestational thrombocytopenia, antiphos-
pholipid syndrome, and even in normal pregnancies [5].
ITP diagnosis is of exclusion. There are no pathog-
nomonic components of this pathology. According to the
American College of Obstetrics and Gynecology (ACOG),
therearesomeelementstraditionallyassociatedwiththisdis-
ease such as: (1) persistent thrombocytopenia (platelet count
<100×109/L with or without megakaryocytes in peripheral
smear), (2) normal or increased medullary megakaryocytes,
(3) exclusion of other systematic diseases or drugs that
are associated with thrombocytopenia, and (4) absence of
splenomegaly [5]( T a b l e1).
The preeclampsia-eclampsia syndrome is determined
by the presence of hypertension in pregnancy with a 24-
hour count of albuminuria >0.3g. An important form of
severe preeclampsia is the HELLP syndrome. This syndrome
was ﬁrst described by Weinstein in 1982. HELLP is an
English acronym that stands for Hemolysis, Elevated Liver
Enzymes and Low Platelets. There are diagnostic criteria
such as the Tennessee Classiﬁcation: evidence of hemolysis
with LDH>600Ul/L or greater or bilirubin 1.2mg/dL or
greater, hepatic dysfunction with AST>70Ul/L or greater,
and platelets <100×109/L or less. It is considered complete
or true if it contains these three components and incomplete
if it has only two. There is a classiﬁcation of severity such as
the Mississippi Classiﬁcation that divides HELLP syndrome
into three classes according to the degree of thrombo-
cytopenia, considering it mild when between 150×109/L
and 100×109/L, moderate when between 100×109/L and
50×109/L, and severe when <50×109/L [6].
2.CaseReport
The patient is a 19-year-old female with chronic ITP
since the age of nine and who is under treatment with2 Obstetrics and Gynecology International
Table 1: Causes of thrombocytopenia during pregnancy [5].
Gestational thrombocytopenia
Hypertension induced by pregnancy
HELLP syndrome
Immune Thrombocytopenic Purpura
HIV infection
Systemic lupus erythematosus
Antiphospholipid syndrome
Hypersplenism
Disseminated intravascular coagulation
Thrombotic thrombocytopenic purpura
Hemolytic uraemic syndrome
Congenital thrombocytopenias
Medications (heparin, zidovudine, quinine, sulphonamides)
Pseudothrombocytopenia
oral Prednisone, 30mg/day. This treatment is not followed
regularly. She is G2, A1 and is admitted to the Pereira-
Rossell Hospital with a 29-week pregnancy due to painful
uterine contractions that subside spontaneously with rest
while hospitalized. For 48 hours and every 12 hours, an
i.m. dose of 6mg Dexamethasone was administered with the
purpose of reducing the occurrence of neonatal respiratory
distress syndrome.
The patient had severe thrombocytopenia episodes dur-
ing the 14, 22, and 26 weeks of gestation, being treated
with Immunoglobulin G, Gamma globulin and Methylpred-
nisolone, respectively.
While hospitalized, she was hypertensive with levels of
150/100mm Hg., accompanied with ecchymoses on right
buttock with no petechiae, and had a platelet count of
3×109/L. The transaminase values showed AST: 284IU/L
and ALT: 362IU/L; LDH: 1,280U/L. The 24-hour albumin-
uria test is of 0.48g. Serum creatinine and hematocrit levels
were normal. One g/kg of weight of Immunoglobulin G was
administered. At the same time, she spontaneously started
labor. Eight concentrates of platelets were administered,
showing a rise up to 100×109/L (Figure 1). The vaginal
deliverywascarriedoutwithouthemorrhagiccomplications,
giving birth to a live newborn weighing 1,142g, with an
Apgar score of 4/6, showing good evolution and presenting
no thrombocytopenia. For 24 hours the patient received
an i.v. dose of 1/g/hour magnesium sulphate. She remaind
normotensive under treatment with a dose of 500mg alpha
methyldope every eight hours. She was given 50mg/day
of oral Prednisone. The value of liver enzymes decreased
returning to normal during the ﬁrst days of puerperium
(Figure 2).
On July 4 (day 12 of puerperium), the patient presented
epistaxis and ecchymoses on one thigh, and her platelet
count was <5×109/L (Figure 3). Six platelet concentrates
were administered, and a three-day treatment with an i.v.
dose of 1g/day Methylprednisolone was started. Later, an
oral dose of 40mg/day Dexamethasone was given for four
days and, ﬁnally, 40g/day of oral Prednisone. An i.v dose
of 2,500mcg Anti-D Immunoglobulin and two i.v. doses
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Figure 1: Platelet count.
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Figure 2: Aminotransferases.
of 2mg Vincristine were administered weekly. Initially, the
patient responded well to the treatment. On day 21 of
puerperium, the patient started a spontaneous epistaxis
and ecchymoses with a platelet count of 5×109/L. Six
platelet concentrates were given. On day 23 of puerperium,
a splenectomy was done by laparotomy. The postoperative
evolution was good, and the patient was discharged from the
hospital on day seven of the treatment with oral Prednisone.
3. Discussion
The concomitance of chronic ITP, preeclampsia-eclampsia
syndrome, and HELLP syndrome is extremely rare. In
January 2010, we did a bibliographical search in PubMed
and Cochrane Database of Systematic Reviews using the
following key words: HELLP Syndrome, Idiopathic Throm-
bocytopenic Purpura, Pregnancy, Autoimmune Diseases and
PreEclampsia. No similar cases were reported.Obstetrics and Gynecology International 3
0
10
20
30
40
50
60
70
80
90
P
l
a
t
e
l
e
t
s
×
1
0
9
/
L
0
4
-
J
u
l
0
6
-
J
u
l
0
8
-
J
u
l
1
0
-
J
u
l
1
2
-
J
u
l
1
4
-
J
u
l
Figure 3: Platelet count.
The platelet count normally decreases during pregnancy
although it is uncommon to have a count below 100×109/L.
In our case, there were three episodes of severe thrombo-
cytopenia that required hospitalization and treatment. In
this case, there was no neonatal thrombocytopenia even
knowing that the antiplatelet antibodies belonged to the lgG
variety which are able to pass through the placenta and
cause fetal and neonatal thrombocytopenia [5]. Neonatal
thrombocytopenia is present in approximately 25% of the
cases, being severe (<50×109/L) in about 10% of the cases.
Approximately 4% of neonates show thrombocytopenia
(<20×109/L). Acute hemorrhagic complications such as
intracranial hemorrhage is a rare event observed in less than
1% of the cases [1, 7–9]. Since fetal platelet destruction is
produced in the reticuloendothelial system, the prematurity
such as the case we are describing could be a protective
factor for fetal compromise, because due to the immaturity
of the reticuloendothelial system, such compromise could be
less serious. It is not possible to predict the risk of fetal or
neonatal thrombocytopenia based on the maternal platelet
count, the presence of antiplatelet antibodies, or previous
splenectomy [1, 5, 10].
The preeclampsia was diagnosed because the patient
was hypertensive with 24-hour albuminuria values of 0.48g.
The liver function test alterations and the thrombocytopenia
correspond to the diagnosis of HELLP syndrome.
As to the mode of delivery, there is no evidence that
the performance of a C-section diminishes the risk of
neonatalintracranialhemorrhage,increasing,inasigniﬁcant
manner, maternal hemorrhagic risks; therefore, it is being
recommended that the mode of delivery be determined
by the obstretic conditions [1, 5]. The British Society of
Hematology recommends that thrombocytopenia counts of
50×109/L are safe for a vaginal delivery, and 80×109/L
are safe for a C-section and spinal or epidural anesthesia
[1]. Nonsteroidal anti-inﬂammatory drugs should not be
prescribed as analgesics.
During pregnancy, ITP treatment depends on the risk of
maternal hemorrhage and on having safe values of platelets
at the moment of delivery [5]. The increase in the platelet
count happens in 70% of the cases with the administration
of Prednisone [5]. In the case we are describing, a treatment
with Prednisone was carried out with an oral dose of
30mg/day that the patient did not follow adequately.
Thei.v.immunoglobulinG,1g/kgofweight,wasadmin-
istered before delivery with a platelet count of 3×109/L.
AccordingtorecommendationsbytheACOG,thisprocedure
would be appropriate for cases of ITP with a platelet count
lower than 10×109/L in the third trimester, lower than
30×109/L associated with bleeding, or as preoperative or
p r i o rt od e l i v e r y[ 5]. Its eﬀect is observed between six and
seventy-two hours after administering the medication. This
eﬀect remains for two to three weeks with a positive response
in 80% of the cases [1].
The transfusion of platelets is reserved for cases of vital
risk when there are acute hemorrhages or when it is time for
delivery, as was our case, or surgery [5].
Another therapeutical option used was the adminis-
tration of i.v. Methylprednisolone, 1g/day, for three days.
After that, the patient was given an oral dose of 40mg/day
Dexamethasone for four days, which has shown to be
eﬀectiveasinitialtreatmentinITPinadults,witharemission
rate of 40%.
During puerperium, a dose of 50mcg/kg of weight Anti-
(Rh) D Immunoglobulin was administered. It is a suitable
treatment for nonsplenectomized Rh (D)-positive patients
[1]. A weekly i.v. dose of 2mg Vincristine was administered
twice. This drug has shown a temporary increase in the
platelet count in two thirds of the patients with ITP, but
there is a lasting remission in about 10% of the patients.
Vincristinehasadverseeﬀectssuchasneutropenia,fever,and
phlebitis [1].
The splenectomy was done on day 23 of the puerperium
because of the unsatisfactory response to the treatment. The
performance of a splenectomy during pregnancy may be
technically diﬃcult due to the size of the uterus after a
20-week pregnancy and may cause spontaneous abortion
during the ﬁrst trimester. If it were necessary to perform
this surgery during pregnancy, the ideal moment would be
in the second trimester. A splenectomy is associated with a
completeremissionofthethrombocytopeniainITPinabout
66% of the patients [5]. Despite this, it does not predict
better neonatal results in future pregnancies. There may be
a maternal clinical improvement, but there is not necessarily
an immunological remission.
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